CorneaGen

Executive Summary

CorneaGen is a privately held ophthalmic company headquartered in Seattle, Washington, dedicated to eliminating corneal blindness worldwide. Founded in 2015, the company operates as a leading eye bank and develops patient-ready, customized corneal tissue inlays and supporting surgical instruments. By providing high-quality donor tissue and advanced processing techniques, CorneaGen aims to transform the treatment of corneal diseases, offering surgeons innovative tools to improve surgical outcomes and patient recovery. The company's integrated model—combining eye banking with tissue engineering and instrument design—positions it uniquely in the regenerative medicine and ophthalmology sectors. With a focus on addressing the global shortage of transplantable corneal tissue, CorneaGen has established a robust supply chain and processing infrastructure. Its customized inlays are designed to match individual patient anatomy, reducing rejection rates and enhancing visual outcomes. The company's surgical instruments are engineered to facilitate precise implantation and minimize trauma. As CorneaGen scales its operations and pursues regulatory approvals for next-generation products, it is poised to capture a significant share of the corneal transplant market, which is driven by aging populations and rising prevalence of keratoconus and other corneal disorders.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for novel customized corneal inlay60% success
• Q4 2026Partnership with major hospital network for tissue distribution70% success
• Q2 2026Launch of next-generation surgical instrument for inlay implantation80% success